NXTC FY 2024 Earnings — NextCure, Inc. Revenue & Financial Results | Market Cap Arena

NXTCNextCure, Inc.

$36M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$60M

Net Income

-$56M

EPS (Diluted)

$-23.88

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$41M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$81M

Total Liabilities

$15M

Stockholders' Equity

$65M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$60M	-$68M	+11.7%
Net Income	-$56M	-$63M	+11.3%